Spots Global Cancer Trial Database for squamous cell carcinoma of the head and neck
Every month we try and update this database with for squamous cell carcinoma of the head and neck cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00402545 | Head and Neck N... | Cetuximab Docetaxel Cisplatin 5-Fluorouracil | 18 Years - | Dana-Farber Cancer Institute | |
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer | NCT05930938 | Squamous Cell C... | Xevinapant Placebo cetuximab IMRT | 18 Years - 79 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00409565 | Head and Neck C... Squamous Cell C... | Cetuximab Bevacizumab | 18 Years - 98 Years | National Cancer Institute (NCI) | |
| Sexual Behavior in Head and Neck Cancer Patients | NCT00662662 | Oropharyngeal C... Head and Neck C... Squamous Cell C... | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| Hyperbaric Radiation Sensitization of Head and Neck Cancers | NCT03843671 | Squamous Cell C... | Hyperbaric oxyg... Hyperbaric cham... | 18 Years - | National Baromedical Services | |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | NCT04609566 | Melanoma Non-small Cell ... Squamous Cell C... | brentuximab ved... pembrolizumab | 18 Years - | Seagen Inc. | |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | NCT02124707 | Head and Neck C... Squamous Cell C... | Cetuximab Paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| CTC Detection Rate in SCCHN With a in Vivo Device | NCT03071900 | Circulating Tum... Squamous Cell C... | circulating tum... | 20 Years - 90 Years | Nanjing Tongren Hospital | |
| Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial | NCT02022098 | Squamous Cell C... | Cisplatin Radiotherapy Debio 1143 Placebo | 18 Years - 75 Years | Debiopharm International SA | |
| Nutrition and Life QUality Patients With Head and Neck Cancers | NCT02510859 | Squamous Cell C... | Systematic nutr... | 18 Years - | University Hospital, Caen | |
| Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | NCT05931445 | Breast Cancer Lung Cancer Colorectal Canc... Liver Cancer Stomach Cancer Endometrial Can... Ovarian Cancer Squamous Cell C... | e-PRO monitorin... | 18 Years - | Comprehensive Support Project for Oncology Research | |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | NCT02686008 | Squamous Cell C... | Olaparib | 18 Years - | Yale University | |
| Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | NCT02296684 | Cancer of Head ... Head and Neck C... Neoplasms, Head... Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | MK-3475 (neoadj... Surgery Intensity modul... Image-guided ra... Cisplatin MK-3475 (adjuva... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT01458392 | Squamous Cell C... | Dalantercept | 18 Years - | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | |
| Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT01104922 | Squamous Cell C... | Cetuximab Stereotactic ra... | 18 Years - | University of Pittsburgh | |
| Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects | NCT01012258 | Squamous Cell C... | Cetuximab + con... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | NCT00625456 | Melanoma Lung Cancer Renal Cell Carc... Squamous Cell C... | Recombinant Vac... | 18 Years - | SillaJen, Inc. | |
| A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | NCT00210470 | Squamous Cell C... | IRX-2 Cyclophosphamid... Indomethacin Zinc Omeprazole | 18 Years - 80 Years | Brooklyn ImmunoTherapeutics, LLC | |
| Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN | NCT03880396 | Squamous Cell C... | hypofractionate... | 18 Years - 75 Years | Assiut University | |
| Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN | NCT01305772 | Squamous Cell C... | Panitumumab Surgery Radiation Thera... | 18 Years - | Duke University | |
| Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） | NCT03855384 | Squamous Cell C... | TQB2450+cisplat... placebo+cisplat... | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| GEN1046 Safety Trial in Patients With Malignant Solid Tumors | NCT03917381 | Solid Tumors Non-small Cell ... Urothelial Carc... Endometrial Car... Triple Negative... Squamous Cell C... Cervical Cancer | Acasunlimab Acasunlimab in ... Acasunlimab in ... Acasunlimab in ... | 18 Years - | Genmab | |
| Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion | NCT03330249 | Squamous Cell C... | Split Cisplatin Cisplatin Radiotherapy | 18 Years - 70 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | NCT02262741 | Squamous Cell C... | MEDI4736 tremelimumab | 18 Years - 99 Years | MedImmune LLC | |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT02277197 | Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | Ficlatuzumab Cetuximab | 18 Years - | University of Pittsburgh | |
| 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck | NCT00257738 | Squamous Cell C... | MAGE-A3 HPV-16 vaccine | 18 Years - 80 Years | University of Maryland, Baltimore | |
| Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies | NCT02369458 | Squamous Cell C... Squamous Cell C... | Mitomycin-C Pegfilgrastim | 18 Years - | Washington University School of Medicine | |
| Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients | NCT02139020 | Squamous Cell C... | Plasma samples | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer | NCT02350712 | Squamous Cell C... | Patritumab Cetuximab Cisplatin Carboplatin | 18 Years - | Daiichi Sankyo | |
| Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT00652613 | Squamous Cell C... | 3 Dimensional R... Intensity Modul... | 18 Years - 65 Years | Tata Memorial Hospital | |
| Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | NCT04034225 | Squamous Cell C... | SNS-301 Pembrolizumab | 18 Years - | Sensei Biotherapeutics, Inc. | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck | NCT03057613 | Squamous Cell C... | Pembrolizumab IMRT 60-66Gy | 18 Years - | Case Comprehensive Cancer Center | |
| Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | NCT04326257 | Squamous Cell C... | Nivolumab+Relat... Nivolumab+Ipili... | 18 Years - | University of Pittsburgh | |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
| Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck | NCT02624128 | Squamous Cell C... | Valproic Acid Cisplatin Cetuximab | 18 Years - | National Cancer Institute, Naples | |
| The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers | NCT02435602 | Esophageal Squa... Squamous Cell C... | NBI endoscopy Lugol chromoend... | 18 Years - | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Expansion Trial for Axitinib In Head And Neck Cancer | NCT02762513 | Squamous Cell C... | Axitinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | NCT03525392 | Pancreatic Duct... Colorectal Canc... Gastric Cancer Squamous Cell C... Bone Cancer Advanced Cancer Recurrent Disea... Metastatic Tumo... | 177Lu-3BP-227 (... | 18 Years - | Ipsen | |
| Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor | NCT00377247 | Primary Advance... Squamous Cell C... | autologous mono... | 37 Years - | University of Pittsburgh | |
| Clinical Study of Pan-cancer DNA Methylation Test in Plasma | NCT05685524 | Cancer | DNA methylation... | 18 Years - 80 Years | Wuhan Ammunition Life-tech Co., Ltd | |
| Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | NCT01054625 | Head and Neck C... | zalutumumab | 18 Years - | Genmab | |
| Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma | NCT06041464 | Squamous Cell C... Cancer | cell culture | - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History | NCT01758731 | Squamous Cell C... | Olaparib Cetuximab Radiation Thera... | 18 Years - | University of Colorado, Denver | |
| Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03139058 | Liver Fibroses Liver Cirrhoses Squamous Cell C... | Evaluation of t... | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | NCT03006887 | Solid Tumors | lenvatinib pembrolizumab | 20 Years - | Eisai Inc. | |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | NCT03083873 | Squamous Cell C... | LN-145 LN-145-S1 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | NCT02575404 | Melanoma Non-Small Cell ... Squamous Cell C... | GR-MD-02 Pembrolizumab | 18 Years - | Providence Health & Services | |
| Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | NCT04152018 | Squamous Cell C... Renal Cell Carc... Ovarian Cancer Gastric Cancer Esophageal Canc... Lung Squamous C... Pancreatic Canc... Bile Duct Cance... Endometrial Can... Melanoma Cancer Urothelial Canc... | PF-06940434 PF-06801591 | 18 Years - | Pfizer | |
| Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | NCT00272181 | Squamous Cell C... Carcinoma, Squa... Neoplasms, Squa... Head and Neck N... Mouth Neoplasms Head and Neck C... | Proxinium | 18 Years - | Sesen Bio, Inc. | |
| Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT01289522 | Squamous Cell H... Recurrent or Me... | cetuximab IV Biopsies | 18 Years - 70 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | NCT01927744 | Head and Neck C... | Docetaxel Erlotinib Placebo Questionnaires Phone Call Chemotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | NCT00736944 | Squamous Cell C... | Abraxane Cetuximab Cetuximab Cisplatin 5-FU Radiation (Post... Cisplatin Cetuximab | 18 Years - | Washington University School of Medicine | |
| A Study of SGN-PDL1V in Advanced Solid Tumors | NCT05208762 | Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer | SGN-PDL1V pembrolizumab | 18 Years - | Seagen Inc. | |
| ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT01218048 | Squamous Cell C... | Cetuximab Surgery Post-surgical r... Cisplatin or ca... | 18 Years - | University of Pittsburgh | |
| Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN | NCT03880396 | Squamous Cell C... | hypofractionate... | 18 Years - 75 Years | Assiut University | |
| Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer | NCT03733210 | Squamous Cell C... Carcinoma of th... | Panitumumab-IRD... 89-Zirconium (Z... Pinpoint IR IR9... SPY-PHI IR9000 ... Explorer Air ca... PDE-NEO II came... FIS-00 fluoresc... Da Vinci Firefl... IGP-ELVIS-v4 Ma... Vevo 3100 LAZR-... Pearl Triology ... Odyssey CLx Ima... Leica fluoresce... | 19 Years - | Stanford University | |
| SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes | NCT02644122 | Metastatic Squa... | SF1126 | 18 Years - | University of California, San Diego | |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | NCT05482880 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer High-Risk Cance... Quality of Life Satisfaction, P... | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| CIML NK Cell in Head & Neck Cancer | NCT04290546 | Squamous Cell C... Recurrent Head ... | Interleukin-15 ... CIML NK cell In... Ipilimumab Cetuximab | 18 Years - | Dana-Farber Cancer Institute | |
| A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | NCT02841748 | Head and Neck C... Squamous Cell C... | Pembrolizumab Placebo | 18 Years - | University of Chicago | |
| Phase II Study of RAD001 Head and Neck Cancer | NCT01051791 | Squamous Cell C... | Everolimus 10mg... | 18 Years - 80 Years | University of Pittsburgh | |
| Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | NCT04453046 | Squamous Cell C... | Hemopurifier Pembrolizumab 2... | 18 Years - | Aethlon Medical Inc. | |
| Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma | NCT00903461 | Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | EGFR Antisense ... | 18 Years - | University of Pittsburgh | |
| A Study of SGN-PDL1V in Advanced Solid Tumors | NCT05208762 | Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer | SGN-PDL1V pembrolizumab | 18 Years - | Seagen Inc. | |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | NCT02452424 | Melanoma Non-small Cell ... Squamous Cell C... Gastrointestina... Ovarian Cancer | PLX3397 Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC | NCT06046625 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer Patient Satisfa... High-Risk Cance... Preference, Pat... Decision Making Interview | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | NCT03098160 | Pancreatic Canc... Melanoma Squamous Cell C... Prostate Cancer | Evofosfamide Ipilimumab | 18 Years - | Threshold Pharmaceuticals | |
| Stereotactic Body Radiotherapy for Head and Neck Tumors | NCT01344356 | Squamous Cell C... Nasopharyngeal ... Salivary Gland ... Head and Neck S... Paraganglioma o... Chordoma of Hea... Chondrosarcoma ... Angiofibroma of... | stereotactic bo... Stereotactic bo... | 18 Years - | Mercy Research | |
| A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | NCT04193293 | Head and Neck S... | Duvelisib Pembrolizumab | 18 Years - | SecuraBio | |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | NCT02158234 | Squamous Cell C... | Cisplatin Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00402545 | Head and Neck N... | Cetuximab Docetaxel Cisplatin 5-Fluorouracil | 18 Years - | Dana-Farber Cancer Institute | |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | NCT03758781 | Metastatic Canc... Recurrent Cance... Solid Tumor Renal Cell Carc... Urothelial Carc... NSCLC Squamous Cell C... Non-Small Cell ... Squamous Cell C... | IRX 2 Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Impact of Ribociclib on Head and Neck Squamous Cell Cancer | NCT03179956 | Squamous Cell C... | Ribociclib | 18 Years - | Fox Chase Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
